NO20041214L - Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer - Google Patents

Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer

Info

Publication number: NO20041214L
Authority: NO; Norway
Prior art keywords: cancer; treatment; benzimidazole compounds; substituted benzimidazole; substituted
Prior art date: 2001-09-26

Application number

NO20041214A

Other languages

English (en)

Other versions

NO327008B1 (no

Inventor

Francois Clerc

Francois Hamy

Isabelle Depaty

Odile Angouillant-Boniface

Chantal Carrez

Manfred Roesner

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-26

Filing date

2004-03-23

Publication date

2004-06-24

2004-03-23 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

2004-06-24 Publication of NO20041214L publication Critical patent/NO20041214L/no

2009-04-06 Publication of NO327008B1 publication Critical patent/NO327008B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20041214A 2001-09-26 2004-03-23 Substituerte benzimidazolforbindelser og deres anvendelse for fremstilling av medikamenter for behandling av cancer NO327008B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP01402460A EP1298125A1 (en)	2001-09-26	2001-09-26	Substituted benzimidazole compounds and their use for the treatment of cancer
PCT/EP2002/011353 WO2003028721A2 (en)	2001-09-26	2002-09-26	Substituted benzimidazole compounds and their use for the treatment of cancer

Publications (2)

Publication Number	Publication Date
NO20041214L true NO20041214L (no)	2004-06-24
NO327008B1 NO327008B1 (no)	2009-04-06

Family

ID=8182891

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20041214A NO327008B1 (no)	2001-09-26	2004-03-23	Substituerte benzimidazolforbindelser og deres anvendelse for fremstilling av medikamenter for behandling av cancer

Country Status (34)

Country	Link
US (1)	US7041668B2 (no)
EP (2)	EP1298125A1 (no)
JP (1)	JP4510450B2 (no)
KR (1)	KR100891439B1 (no)
CN (1)	CN100346786C (no)
AR (1)	AR037096A1 (no)
AT (1)	ATE386517T1 (no)
AU (1)	AU2002337151B2 (no)
BR (1)	BR0212856A (no)
CA (1)	CA2461622C (no)
CO (1)	CO5570675A2 (no)
CY (1)	CY1107953T1 (no)
DE (1)	DE60225159T2 (no)
DK (1)	DK1432417T3 (no)
EA (1)	EA006802B1 (no)
ES (1)	ES2301682T3 (no)
GT (1)	GT200200190A (no)
HR (1)	HRPK20040293B3 (no)
HU (1)	HUP0401756A3 (no)
IL (1)	IL161059A0 (no)
ME (1)	MEP16808A (no)
MX (1)	MXPA04002042A (no)
MY (1)	MY135339A (no)
NO (1)	NO327008B1 (no)
NZ (1)	NZ531246A (no)
PA (1)	PA8555501A1 (no)
PE (1)	PE20030427A1 (no)
PL (1)	PL369527A1 (no)
PT (1)	PT1432417E (no)
RS (1)	RS50896B (no)
SI (1)	SI1432417T1 (no)
UY (1)	UY27452A1 (no)
WO (1)	WO2003028721A2 (no)
ZA (1)	ZA200401887B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070010573A1 (en)	2003-06-23	2007-01-11	Xianqi Kong	Methods and compositions for treating amyloid-related diseases
AU2011250847B2 (en) *	2003-06-23	2013-06-20	Bhi Limited Partnership	Methods and compositions for treating amyloid-related diseases
AU2004283313A1 (en) *	2003-10-24	2005-05-06	Exelixis, Inc.	TAO kinase modulators and methods of use
DE102004010207A1 (de)	2004-03-02	2005-09-15	Aventis Pharma S.A.	Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
FR2868421B1 (fr) *	2004-04-01	2008-08-01	Aventis Pharma Sa	Nouveaux benzothiazoles et leur utilisation comme medicaments
EP1598348A1 (en)	2004-05-18	2005-11-23	Aventis Pharma Deutschland GmbH	Novel pyridazinone derivatives as inhibitors of CDK2
CA2900876A1 (en)	2004-12-22	2006-08-17	Bhi Limited Partnership	Methods and compositions for treating amyloid-related diseases
CN101300251B (zh) *	2005-09-06	2011-08-03	史密丝克莱恩比彻姆公司	作为plk抑制剂的苯并咪唑噻吩化合物
FR2891273B1 (fr) *	2005-09-27	2007-11-23	Aventis Pharma Sa	NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet
PL3851447T3 (pl)	2006-10-12	2024-03-04	Bellus Health Inc.	Sposoby, związki, kompozycje i nośniki dostarczające kwas 3-amino-1-propanosulfonowy
PA8792501A1 (es)	2007-08-09	2009-04-23	Sanofi Aventis	Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
NZ583209A (en) *	2007-10-12	2012-06-29	Abbott Lab	2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1
FR2922550B1 (fr)	2007-10-19	2009-11-27	Sanofi Aventis	Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
FR2941951B1 (fr)	2009-02-06	2011-04-01	Sanofi Aventis	Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr)	2009-02-06	2011-04-01	Sanofi Aventis	Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941949B1 (fr)	2009-02-06	2011-04-01	Sanofi Aventis	Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr)	2009-02-06	2011-04-01	Sanofi Aventis	Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
WO2011091152A1 (en) *	2010-01-22	2011-07-28	Pablo Gastaminza	Inhibitors of hepatitis c virus infection
CA2892160C (en)	2012-12-05	2021-03-23	Anna Borodovsky	Pcsk9 irna compositions and methods of use thereof
MX2018002158A (es)	2015-08-25	2018-07-06	Alnylam Pharmaceuticals Inc	MíTODOS Y COMPOSICIONES PARA TRATAR UN TRASTORNO ASOCIADO A GEN DE PROPROTEINA CONVERTASA SUBTILISINA KEXINA (PCSK9).

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2441201C2 (de) *	1974-08-28	1986-08-07	Hoechst Ag, 6230 Frankfurt	Anthelminthisch wirksame 2-Carbalkoxyamino-5(6)-phenyl-sulfonyloxy-benzimidazole und Verfahren zu ihrer Herstellung
DE2541752A1 (de) *	1975-09-19	1977-03-24	Hoechst Ag	Anthelminthisch wirksame 2-carbalkoxyamino-5(6)-phenyl-sulfonyloxy- benzimidazole und verfahren zu ihrer herstellung
DE3247615A1 (de) *	1982-12-23	1984-07-05	Hoechst Ag, 6230 Frankfurt	Substituierte phenylsulfonyloxybenzimidazolcarbaminate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB9900752D0 (en) *	1999-01-15	1999-03-03	Angiogene Pharm Ltd	Benzimidazole vascular damaging agents
US6693125B2 (en) *	2001-01-24	2004-02-17	Combinatorx Incorporated	Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders

2001
- 2001-09-26 EP EP01402460A patent/EP1298125A1/en not_active Withdrawn
2002
- 2002-09-17 PE PE2002000913A patent/PE20030427A1/es not_active Application Discontinuation
- 2002-09-24 UY UY27452A patent/UY27452A1/es unknown
- 2002-09-25 GT GT200200190A patent/GT200200190A/es unknown
- 2002-09-25 MY MYPI20023586A patent/MY135339A/en unknown
- 2002-09-26 AU AU2002337151A patent/AU2002337151B2/en not_active Ceased
- 2002-09-26 ME MEP-168/08A patent/MEP16808A/xx unknown
- 2002-09-26 CA CA002461622A patent/CA2461622C/en not_active Expired - Fee Related
- 2002-09-26 SI SI200230686T patent/SI1432417T1/sl unknown
- 2002-09-26 DK DK02772370T patent/DK1432417T3/da active
- 2002-09-26 WO PCT/EP2002/011353 patent/WO2003028721A2/en not_active Ceased
- 2002-09-26 IL IL16105902A patent/IL161059A0/xx unknown
- 2002-09-26 MX MXPA04002042A patent/MXPA04002042A/es active IP Right Grant
- 2002-09-26 RS YUP-214/04A patent/RS50896B/sr unknown
- 2002-09-26 HU HU0401756A patent/HUP0401756A3/hu unknown
- 2002-09-26 NZ NZ531246A patent/NZ531246A/en not_active IP Right Cessation
- 2002-09-26 DE DE60225159T patent/DE60225159T2/de not_active Expired - Lifetime
- 2002-09-26 PA PA20028555501A patent/PA8555501A1/es unknown
- 2002-09-26 BR BR0212856-0A patent/BR0212856A/pt not_active IP Right Cessation
- 2002-09-26 EP EP02772370A patent/EP1432417B1/en not_active Expired - Lifetime
- 2002-09-26 AT AT02772370T patent/ATE386517T1/de active
- 2002-09-26 CN CNB028187458A patent/CN100346786C/zh not_active Expired - Fee Related
- 2002-09-26 JP JP2003532053A patent/JP4510450B2/ja not_active Expired - Fee Related
- 2002-09-26 KR KR1020047004365A patent/KR100891439B1/ko not_active Expired - Fee Related
- 2002-09-26 HR HR20040293A patent/HRPK20040293B3/xx not_active IP Right Cessation
- 2002-09-26 PL PL02369527A patent/PL369527A1/xx not_active Application Discontinuation
- 2002-09-26 AR ARP020103629A patent/AR037096A1/es unknown
- 2002-09-26 PT PT02772370T patent/PT1432417E/pt unknown
- 2002-09-26 EA EA200400475A patent/EA006802B1/ru not_active IP Right Cessation
- 2002-09-26 ES ES02772370T patent/ES2301682T3/es not_active Expired - Lifetime
2004
- 2004-03-08 ZA ZA200401887A patent/ZA200401887B/en unknown
- 2004-03-23 NO NO20041214A patent/NO327008B1/no not_active IP Right Cessation
- 2004-03-25 US US10/808,889 patent/US7041668B2/en not_active Expired - Fee Related
- 2004-03-25 CO CO04028337A patent/CO5570675A2/es not_active Application Discontinuation
2008
- 2008-05-20 CY CY20081100526T patent/CY1107953T1/el unknown

Also Published As

Publication number	Publication date
CN1558761A (zh)	2004-12-29
WO2003028721A2 (en)	2003-04-10
GT200200190A (es)	2003-11-11
HK1068551A1 (en)	2005-04-29
IL161059A0 (en)	2004-08-31
CA2461622C (en)	2008-12-02
US20050014811A1 (en)	2005-01-20
UY27452A1 (es)	2003-02-28
EA200400475A1 (ru)	2004-08-26
AR037096A1 (es)	2004-10-20
EP1432417B1 (en)	2008-02-20
DK1432417T3 (da)	2008-06-16
SI1432417T1 (sl)	2008-08-31
WO2003028721A3 (en)	2003-12-11
HRP20040293A2 (en)	2005-06-30
EA006802B1 (ru)	2006-04-28
JP4510450B2 (ja)	2010-07-21
MY135339A (en)	2008-03-31
HUP0401756A2 (hu)	2005-01-28
JP2005504112A (ja)	2005-02-10
NZ531246A (en)	2006-06-30
CY1107953T1 (el)	2013-09-04
PL369527A1 (en)	2005-05-02
CN100346786C (zh)	2007-11-07
HRPK20040293B3 (hr)	2007-06-30
EP1298125A1 (en)	2003-04-02
ZA200401887B (en)	2005-05-31
CO5570675A2 (es)	2005-10-31
MXPA04002042A (es)	2004-06-07
BR0212856A (pt)	2004-09-14
DE60225159T2 (de)	2009-02-19
US7041668B2 (en)	2006-05-09
AU2002337151B2 (en)	2007-04-26
MEP16808A (en)	2010-06-10
YU21404A (sh)	2006-08-17
KR20040048904A (ko)	2004-06-10
PE20030427A1 (es)	2003-06-20
ATE386517T1 (de)	2008-03-15
HUP0401756A3 (en)	2005-06-28
DE60225159D1 (de)	2008-04-03
NO327008B1 (no)	2009-04-06
PT1432417E (pt)	2008-05-23
PA8555501A1 (es)	2003-06-30
RS50896B (sr)	2010-08-31
CA2461622A1 (en)	2003-04-10
KR100891439B1 (ko)	2009-04-03
ES2301682T3 (es)	2008-07-01
EP1432417A2 (en)	2004-06-30

Publication	Publication Date	Title
NO20041214L (no)	2004-06-24	Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
NO20024610L (no)	2002-11-25	Synergistiske metoder og blandinger for behandling av kreft
EE05481B1 (et)	2011-10-17	Kinasoliini derivaadid kasvajate raviks
NO20041216L (no)	2004-05-05	Imidazol-4-karboksamidderivater, fremstilling og anvendelse derav for behandling av overvekt
KR100695846B9 (ko)	2021-09-30	암 치료
PL370029A1 (en)	2005-05-16	2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
EE05507B1 (et)	2012-02-15	Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
NO20052760D0 (no)	2005-06-07	Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
NO20052894D0 (no)	2005-06-14	4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
NO20016149D0 (no)	2001-12-17	Indol-derivater og deres anvendelse for behandling av osteporose blant andre applikasjoner
NO20043370L (no)	2004-09-28	N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer
EE200200571A (et)	2004-04-15	Hüdroksüfenüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
IS6917A (is)	2003-08-18	Epóþílon afleiður til meðhöndlunar erfiðra æxla
DK1176964T3 (da)	2007-01-15	Brug af ET743 til behandling af cancer
DE60229959D1 (de)	2009-01-02	Kombinationstherapie zur behandlung von krebs
IS6966A (is)	2003-09-24	Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
IS6967A (is)	2003-09-24	Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
PL356784A1 (pl)	2004-07-12	Substancja do zastosowania w leczeniu łuszczycy
DE60223576D1 (de)	2007-12-27	Hautbehandlungszusammensetzung
NO20033498L (no)	2003-08-07	Fremgangsmåte for behandling og törking av trevirke
EE200200577A (et)	2004-06-15	Kinolinüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
EE200200511A (et)	2004-02-16	Hüdroksüfenüülpiperasinüülmetüülbensamiidi derivaadid valu raviks
DK1355668T3 (da)	2008-05-05	Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom
DE60222664D1 (de)	2007-11-08	Hautbehandlungsmittel
DK1496918T3 (da)	2023-05-15	Anvendelse af natriummetaarsenit til behandling af tumorer

Legal Events

Date	Code	Title	Description
2011-05-09	MM1K	Lapsed by not paying the annual fees